title: Topical ganciclovir in the treatment of acute herpetic keratitis.
abstract: Herpetic keratitis is caused by herpes simplex virus (HSV) and is a common cause of corneal blindness. Following a primary ocular herpetic infection, latency of the virus occurs, followed by subsequent recurrences of herpetic keratitis. Such recurrences may lead to structural damage of the cornea. Recurrent herpetic keratitis is a common indication for corneal transplantation. Recurrences of herpetic keratitis in the corneal graft may lead to corneal graft rejection. Several antiviral agents for HSV are available, including the thymidine analogs. Prolonged use of thymidine analogs may lead to toxicity of the ocular surface, including epithelial keratitis, corneal ulcers, follicular conjunctivitis, and punctal occlusions. Availability of topical antiviral agents that are safe and effective in the treatment and prophylaxis of herpetic keratitis is highly desirable. Ganciclovir is a potent inhibitor of members of the herpes virus family. The drug has been used systemically for the treatment of cytomegalovirus (CMV) retinitis. Its hematologic toxicity secondary to systemic administration led to its limited use in herpetic infections. On the other hand, topical ganciclovir has been shown to be as safe and effective as acyclovir in the treatment of herpetic epithelial keratitis. Furthermore, topical ganciclovir can reach therapeutic levels in the cornea and aqueous humor following topical application. Several clinical trials have shown that topical ganciclovir 0.15% ophthalmic gel is safe and effective in the treatment and prophylaxis of herpetic epithelial disease. Long-term use of ganciclovir ophthalmic gel in patients with penetrating keratoplasty following herpetic keratitis has prevented recurrences of the disease. Topical ganciclovir ophthalmic gel is well tolerated, does not cause toxic effects on the ocular surface, and does not cause hematologic abnormalities. Clinical studies have underscored the potential role of ganciclovir ophthalmic gel in the treatment and prophylaxis of herpetic epithelial keratitis. Future randomized, controlled, multicenter, prospective clinical trials are needed to assess the long-term safety and efficacy of topical ganciclovir in the treatment and prevention of herpetic keratitis and uveitis.
authors.affiliation: The Eye Center and The Eye Foundation for Research in Ophthalmology, Riyadh, Kingdom of Saudi Arabia. k.tabbara@nesma.net.sa
authors.forename: Khalid F
authors.initials: KF
authors.lastname: Tabbara
authors.forename: Noorjehan
authors.initials: N
authors.lastname: Al Balushi
references.citation: Ocul Immunol Inflamm. 1999 Mar;7(1):51-60
references.pmid: 10410875
references.citation: Int Ophthalmol. 2008 Jun;28(3):223-32
references.pmid: 17634865
references.citation: Curr Eye Res. 1987 Jan;6(1):247-53
references.pmid: 3030646
references.citation: Antivir Chem Chemother. 2001 May;12(3):175-86
references.pmid: 12959326
references.citation: Antiviral Res. 1987 Feb;7(2):119-25
references.pmid: 3495237
references.citation: Ophthalmology. 1994 Dec;101(12):1871-82
references.pmid: 7997323
references.citation: Br J Ophthalmol. 2010 Dec;94(12):1648-52
references.pmid: 20576767
references.citation: Ophthalmology. 1987 Aug;94(8):935-44
references.pmid: 3309775
references.citation: Clin Ophthalmol. 2007 Dec;1(4):441-53
references.pmid: 19668521
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002898
references.pmid: 17253484
references.citation: Trans Am Ophthalmol Soc. 2000;98:505-32
references.pmid: 11190039
references.citation: N Engl J Med. 1998 Jul 30;339(5):300-6
references.pmid: 9696640
references.citation: Ophthalmology. 1989 Nov;96(11):1587-96
references.pmid: 2694048
references.citation: Am J Ophthalmol. 1990 Jun 15;109(6):689-95
references.pmid: 2346198
references.citation: J Ocul Pharmacol Ther. 2005 Dec;21(6):463-74
references.pmid: 16386088
references.citation: Am J Med. 1988 Aug 29;85(2A):14-9
references.pmid: 3044076
references.citation: J Med Virol. 1993;Suppl 1:45-50
references.pmid: 8245892
references.citation: Med Oral Patol Oral Cir Bucal. 2011 Jan 01;16(1):e15-8
references.pmid: 20526251
references.citation: J Fr Ophtalmol. 2004 May;27(5):547-57
references.pmid: 15179314
references.citation: Arch Ophthalmol. 2003 Jan;121(1):108-12
references.pmid: 12523894
references.citation: J Infect Dis. 1994 Jun;169(6):1338-41
references.pmid: 8195614
references.citation: Cornea. 1997 Jul;16(4):393-9
references.pmid: 9220235
references.citation: Ophthalmology. 1992 Dec;99(12):1805-8
references.pmid: 1336155
references.citation: Ophthalmology. 2005 Sep;112(9):1640
references.pmid: 16139674
references.citation: Arch Ophthalmol. 2000 Aug;118(8):1030-6
references.pmid: 10922194
references.citation: Curr Eye Res. 1987 Jan;6(1):241-5
references.pmid: 3030645
references.citation: Cornea. 2001 Mar;20(2):187-90
references.pmid: 11248827
references.citation: Br J Ophthalmol. 1996 Feb;80(2):140-3
references.pmid: 8814744
references.citation: J Immunol. 2010 Feb 15;184(4):1867-75
references.pmid: 20089700
references.citation: J Ocul Pharmacol. 1994 Summer;10(2):439-51
references.pmid: 8083563